Foundation for the National Institutes of Health

We are looking forward to hearing from researcher Matthew Greenblatt, MD, PhD, at the 2026 AAP/ASCI/APSA Joint Meeting on April 18. Dr. Greenblatt’s talk, “A new stem cell basis for skeletal pathology,” will highlight the pioneering work that helped earn him the 2025 Paul-Gallin Trailblazer Prize for Physician-Scientists. The FNIH is now accepting nominations for the 2026 Trailblazer Prize, which offers a $100,000 honorarium. Nominate an outstanding researcher now at FNIH.org/trailblazer.

From lab to clinic and bench to bedside, physician-scientists advance discoveries that change lives. The Paul-Gallin Trailblazer Prize for Physician-Scientists honors early- to mid-career investigators who are accelerating solutions that will shape future treatments and cures. We invite nominations from across institutions, disciplines, and scientific communities nationwide. FNIH.org/trailblazerpri…. #TrailblazerPrize #BridgestoBreakthroughs #NextGenScientists #BiomedicalResearch #FNIHAwards

Life science communicators: The deadline to apply for the Kovler Prize for Trust in Life Science Journalism is April 10 at 5 p.m. ET. Don't miss this opportunity to highlight your work! Journalists who work in print, video, digital, or broadcast media are eligible — and the award comes with a $25,000 honorarium. There is no fee to apply. FNIH.org/kovlerprize #KovlerPrize #ScienceJournalismAward #LifeScienceReporting #FNIH

The Kovler Prize for Trust in Life Science Journalism honors communicators who bridge the gap between scientific discovery and public understanding. Journalists who work in print, video, digital, and or broadcast media are all eligible — and the award comes with a $25,000 honorarium. Entries are due April 10 at 5 p.m. ET. Submit a nomination: FNIH.org/kovlerprize

The Paul-Gallin Trailblazer Prize for Physician-Scientists honors exceptional researchers whose discoveries are advancing human health. This is a great opportunity to recognize the outstanding range of talent shaping biomedical science today. FNIH.org/trailblazer #TrailblazerPrize #BridgestoBreakthroughs #NextGenScientists #BiomedicalResearch #FNIHAwards

There’s still time to apply for the Kovler Prize for Trust in Life Science Journalism. This award honors reporting that bridges the gap between scientific discovery and public understanding – and it comes with a $25,000 honorarium. Submit your work or nominate a peer today. FNIH.org/kovlerprize #KovlerPrize #ScienceJournalismAward #LifeScienceReporting #FNIH

Life science communicators: The deadline to apply for the Kovler Prize for Trust in Life Science Journalism is March 27 at 5 p.m. ET. Don't miss this opportunity to highlight your work! Journalists who work in print, video, digital, or broadcast media are eligible — and the award comes with a $25,000 honorarium. FNIH.org/kovlerprize

The FNIH is excited to help initiate this important new partnership.

Exciting news: The FDA has accepted the Qualification Plan for a urine biomarker panel to be used in conjunction with standard laboratory tests to indicate response to drug-induced injury to the kidneys. Learn more: fnih.org/news/urine-bio… @CPathInstitute @NIDDKgov

The FNIH Biomarkers Consortium’s Treatments Against RA and Effect on FDG PET-CT (TARGET Biomarker Study) project sought to evaluate the connection between rheumatoid arthritis therapies and cardiovascular disease risk. As the project comes to a close, Principal Investigators Drs. Dan Solomon and Joan Bathon reflect on how the project’s accomplishments have improved researchers’ ability to predict increases in CVD risk, and how that may lead to new treatments for both RA and CVD. Learn more: fnih.org/our-programs/b…

The FNIH joins the nation today in honoring the life of former President Jimmy Carter. President Carter’s extensive legacy includes his work to improve the health of our nation and people around the world. Please take a moment today to honor this incredible legacy.

The #NIHCommonFund #ComplementARIE program has released a new #FundingOpportunity for a Coordinating Center and Data Hub. Learn how you can contribute to accelerating development of #NewApproachMethodologies: go.nih.gov/3MBEmGy.

A recent thematic issue of the Journal of Clinical and Translational Science highlights insights from the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. Launched at the onset of the COVID-19 pandemic, ACTIV brought together experts from the NIH, the FNIH, and over 30 organizations to fast-track the development of treatments and other therapeutics for COVID-19. Over nearly five years, the program launched 11 master protocols, evaluating 37 therapeutic agents across diverse patient settings. The collection of articles, written and edited by several key members of the ACTIV team, underscores key strategies for addressing public health emergencies, including: 🤝 fostering strong public-private partnerships, 📢 engaging communities to ensure diverse trial participation, and 🏥 designing flexible, adaptive clinical trials. By sharing these lessons, we aim to equip future healthcare leaders and researchers with the tools to respond effectively to emerging global health challenges. Read the full issue: cambridge.org/core/journals/…

What better time than the holidays to express our gratitude for our partners in government, academia, life science organizations, and patient advocacy. It takes all of us to make a difference. Learn more about our mission ://fnih.org/

The FNIH values our partnerships with amazing people like Parkinson’s advocate Dr. @SoaniaMathur, who shares her insights and lived experiences to support our Accelerating Medicines Partnership® for Parkinson’s Disease and Related Disorders. brainandlife.org/articles/mothe… @PdAvengers

Thank you to everyone who helped build bridges to breakthroughs on #GivingTuesday! Your support will accelerate medical research designed to bring life-changing solutions to those who need them most, and we are #grateful! Learn more: fnih.org/giving-tuesday/

HOPE — it’s embedded in everything we do — from supporting innovative research to funding exceptional scientists. Make a gift to the FNIH on #GivingTuesday, and you will help accelerate and amplify medical breakthroughs that bring hope to millions. fnih.org/giving-tuesday/

The FNIH is supporting team research that has led to a better understanding of the underlying biology of Alzheimer’s disease and is now translating into innovative solutions for improving patient outcomes. FNIH partners Joel Braunstein, C2N Diagnostics, and Diane Stephenson and Klaus Romero, Critical Path Institute, reflected recently on both the outstanding progress in the field of Alzheimer’s disease and the challenges ahead. #AlzheimersAwarenessMonth